Amendment To License Agreement Sample Contracts

Synthorx, Inc. – First Amendment to License Agreement (November 13th, 2018)
Axonics Modulation Technologies, Inc. – Second Amendment to License Agreement (October 5th, 2018)
Axonics Modulation Technologies, Inc. – Amendment to License Agreement (October 5th, 2018)
Synthorx, Inc. – First Amendment to License Agreement (October 2nd, 2018)
Cytomedix, Inc. New – First Amendment to License Agreement (October 2nd, 2018)

This FIRST AMENDMENT ("Amendment") is made and entered into as of September 28, 2018 ("Amendment Effective Date"), between Aldagen, Inc., a Delaware corporation ("ALDAGEN"), with its principal offices at 207A Perry Parkway, Suite 1, Gaithersburg, MD 20877, and STEMCELL Technologies Canada Inc. (previous corporate name being STEMCELL Technologies, Inc.), a company with its principal office at 1618 Station Street, Vancouver, BC, Canada V6A 1B6 ("STEMCELL"). Each of ALDAGEN and STEMCELL is hereinafter referred to as a "Party" and collectively the "Parties."

Axonics Modulation Technologies, Inc. – Second Amendment to License Agreement (August 28th, 2018)
Axonics Modulation Technologies, Inc. – Amendment to License Agreement (August 28th, 2018)
Biohaven Pharmaceutical Holding Co Ltd. – AMENDMENT to LICENSE AGREEMENT Between BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. And BRISTOL-MYERS SQUIBB COMPANY (August 14th, 2018)

This AMENDMENT (this "Amendment") dated as of the date last signed by a party below (the "Amendment Date") is made to the License Agreement dated July 8, 2016 (the "License Agreement") between Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 345 Park Avenue, New York, New York 10154 ("BMS"), and Biohaven Pharmaceutical Holding Company Ltd., a British Virgin Islands business company, with its registered office address of P.O. Box 173, Kingston Chambers, Road Town, Tortola, British Virgin Islands ("Company"). BMS and Company are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Aclaris Therapeutics, Inc. – First Amendment to License Agreement (August 3rd, 2018)

Vixen Pharmaceuticals, a Delaware corporation, as assigned to and assumed by Aclaris Therapeutics Inc., having offices at 640 Lee Road, Suite 200, Wayne, Pennsylvania 19087 ("RECIPIENT") pursuant to the Stock Purchase Agreement signed by Vixen Pharmaceuticals and Aclaris Therapeutics Inc., dated March 24, 2015; and

AgeX Therapeutics, Inc. – First Amendment to License Agreement (July 19th, 2018)

THIS FIRST AMENDMENT TO LICENSE AGREEMENT ("First Amendment") is entered into on November 8, 2017 (the "Effective Date") by and between BIOTIME, INC., a California corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 ("BioTime"), and AGEX THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 ("AgeX").

Aridis Pharmaceuticals, Inc. – First Amendment to License Agreement (July 18th, 2018)

This First Amendment to License Agreement (the Amendment) is entered into as of the 10th day of January 2017 (the Effective Date) by and between the University of Iowa Research Foundation (UIRF), and Aridis Pharmaceuticals, Inc (Licensee).

BioNano Genomics, Inc – Second Amendment to License Agreement (June 28th, 2018)

AMENDMENT dated as of February 25, 2010, to the License Agreement (Agreement) with an Effective Date of January 7th, 2004 between PRINCETON UNIVERSITY, a not-for-profit corporation duly organized and existing under the laws of the State of New Jersey and having a principal place of business at 4 New South Building, Princeton, New Jersey 08544-0036, United States of America, (PRINCETON) and BIONANOMATRIX, LLC., a limited liability corporation duly organized and existing under the laws of the State of Delaware (hereinafter referred to as BioNanomatrix).

BioNano Genomics, Inc – Third Amendment to License Agreement (June 28th, 2018)

AMENDMENT dated as of October 17, 2011, to the License Agreement with an Effective Date of January 7th, 2004 between PRINCETON UNIVERSITY, a not-for-profit corporation duly organized and existing under the laws of the State of New Jersey and having a principal place of business at 4 New South Building, Princeton, New Jersey 08544-0036, United States of America, (PRINCETON) and BIONANOMATRIX, Inc, a corporation duly organized and existing under the laws of the State of Delaware (hereinafter referred to as Licensee).

BioNano Genomics, Inc – First Amendment to License Agreement (June 28th, 2018)

AMENDMENT dated as of December 17, 2004, to the License Agreement with an Effective Date of January 7th, 2004 between PRINCETON UNIVERSITY, a not-for-profit corporation duly organized and existing under the laws of the State of New Jersey and having a principal place of business at 4 New South Building, Princeton, New Jersey 08544-0036, United States of America, (PRINCETON) and BIONANOMATRIX LLC, a limited liability company duly organized and existing under the laws of the State of Delaware (hereinafter referred to as Licensee).

BioNano Genomics, Inc – Fourth Amendment to License Agreement (June 28th, 2018)

AMENDMENT dated as of February 9th, 2012, to the License Agreement (Agreement) with an Effective Date of January 7th, 2004 between PRINCETON UNIVERSITY, a not-for- profit corporation duly organized and existing under the laws of the State of New Jersey and having a principal place of business at 4 New South Building, Princeton, New Jersey 08544-0036, United States of America, (PRINCETON) and BIONANO GENOMICS, INC., a corporation duly organized and existing under the laws of the State of Delaware (hereinafter referred to as BioNano Genomics).

Cue Biopharma, Inc. – First Amendment to License Agreement (June 20th, 2018)

This First Amendment to License Agreement (this First Amendment), is made as of the 18th day of June, 2018, by and between Cue Biopharma, Inc., a Delaware corporation having a place of business located at 675 W. Kendall Street, Cambridge, Massachusetts (Licensee) and MIL 21E, LLC, a Delaware limited liability company having a place of business located at 675 West Kendall Street, Cambridge, MA 02142 (Licensor).

Immudyne Inc – First Amendment to License Agreement (June 8th, 2018)

This First Amendment (the "Amendment") to the License Agreement dated November 26, 2017 (the "License Agreement"), is made and entered into effective as of May 20, 2018 (the "Effective Date"), by and between Immudyne PR, a Puerto Rico domiciled limited liability company ("Immudyne PR or the "Licensee"), One Down, a limited liability company with a place of business at 550 Military Trail, Jupiter, FL 33458 ("One Down" or the "Licensor") and Immudyne, a Delaware domiciled corporation with a place of business at 1460 Broadway, New York NY 10036 ("Immudyne"). Capitalized terms used but not otherwise defined herein shall have the same meanings as set forth in the Services Agreement attached as Appendix A to this First Amendment.

BioNano Genomics, Inc – First Amendment to License Agreement (May 14th, 2018)

AMENDMENT dated as of December 17, 2004, to the License Agreement with an Effective Date of January 7th, 2004 between PRINCETON UNIVERSITY, a not-for-profit corporation duly organized and existing under the laws of the State of New Jersey and having a principal place of business at 4 New South Building, Princeton, New Jersey 08544-0036, United States of America, (PRINCETON) and BIONANOMATRIX LLC, a limited liability company duly organized and existing under the laws of the State of Delaware (hereinafter referred to as Licensee).

BioNano Genomics, Inc – Fourth Amendment to License Agreement (May 14th, 2018)

AMENDMENT dated as of February 9th, 2012, to the License Agreement (Agreement) with an Effective Date of January 7th, 2004 between PRINCETON UNIVERSITY, a not-for- profit corporation duly organized and existing under the laws of the State of New Jersey and having a principal place of business at 4 New South Building, Princeton, New Jersey 08544-0036, United States of America, (PRINCETON) and BIONANO GENOMICS, INC., a corporation duly organized and existing under the laws of the State of Delaware (hereinafter referred to as BioNano Genomics).

BioNano Genomics, Inc – Third Amendment to License Agreement (May 14th, 2018)

AMENDMENT dated as of October 17, 2011, to the License Agreement with an Effective Date of January 7th, 2004 between PRINCETON UNIVERSITY, a not-for-profit corporation duly organized and existing under the laws of the State of New Jersey and having a principal place of business at 4 New South Building, Princeton, New Jersey 08544-0036, United States of America, (PRINCETON) and BIONANOMATRIX, Inc, a corporation duly organized and existing under the laws of the State of Delaware (hereinafter referred to as Licensee).

BioNano Genomics, Inc – Second Amendment to License Agreement (May 14th, 2018)

AMENDMENT dated as of February 25, 2010, to the License Agreement (Agreement) with an Effective Date of January 7th, 2004 between PRINCETON UNIVERSITY, a not-for-profit corporation duly organized and existing under the laws of the State of New Jersey and having a principal place of business at 4 New South Building, Princeton, New Jersey 08544-0036, United States of America, (PRINCETON) and BIONANOMATRIX, LLC., a limited liability corporation duly organized and existing under the laws of the State of Delaware (hereinafter referred to as BioNanomatrix).

Therapix Biosciences Ltd. – Second Amendment to License Agreement (April 30th, 2018)

THIS SECOND AMENDMENT TO LICENSE AGREEMENT (the "Second Amendment") is made as of September 17, 2017 by and between Dekel Pharmaceuticals Ltd. (the "Licensor" or "Dekel"), and Therapix Biosciences Ltd., (the "Licensee" or "Therapix"). Licensee, on the one hand, and Licensor, on the other, may each individually be referred to in this Amendment as a "Party" and collectively referred to in this Amendment as the "Parties".

Aridis Pharmaceuticals, Inc. – First Amendment to License Agreement (April 20th, 2018)

This First Amendment to License Agreement (the Amendment) is entered into as of the 10th day of January 2017 (the Effective Date) by and between the University of Iowa Research Foundation (UIRF), and Aridis Pharmaceuticals, Inc (Licensee).

First Amendment to License Agreement (April 11th, 2018)

This First Amendment to License Agreement (First Amendment), is entered on January 5, 2017, by and among RAW ENERGY MATERIALS, CORP., a Florida corporation (Licensor or Raw Energy) and ROCKSTAR ACQUISITIONS, LLC, a Florida limited liability company, (Licensee or Rockstar Acquisitions). [Each is a Party and together are the Parties. All initially capitalized terms used in this First Amendment shall have the same meanings ascribed to them in the License Agreement.]

Audentes Therapeutics, Inc. – FIRST AMENDMENT TO License Agreement (March 9th, 2018)

This FIRST AMENDMENT TO LICENSE AGREEMENT ("First Amendment") is entered into as of November 3, 2017 ("First Amendment Effective Date") by and between REGENXBIO Inc., a corporation organized under the laws of the State of Delaware, with offices at 9600 Blackwell Road, Suite 210, Rockville, MD 20850 ("Licensor"), and Audentes Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 600 California Street, 17th Floor, San Francisco, California, 94108 ("Licensee"). Licensor and Licensee are hereinafter referred to individually as a "Party" and collectively as the "Parties."

Fourth Amendment to License Agreement (March 6th, 2018)

This Fourth Amendment to License Agreement (this "Fourth Amendment") is entered into as of this 5th day of December, 2017 (the "Fourth Amendment Effective Date"), by and between Tetraphase Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 480 Arsenal Street, Suite 110, Watertown, MA 02472 ("Licensee") and President and Fellows of Harvard College, Richard A. and Susan F. Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, MA 02138 ("Harvard").

REGENXBIO Inc. – First Amendment to License Agreement (March 6th, 2018)

This First Amendment to License Agreement (the "First Amendment") is made as of January 8, 2018 (the "First Amendment Effective Date") by and between REGENXBIO Inc. (formerly known as ReGenX Biosciences, LLC), a corporation organized under the laws of the State of Delaware, with offices at 9600 Blackwell Road, Suite 210, Rockville, MD 20850 ("Licensor"), and AveXis, Inc., a corporation organized under the laws of the State of Delaware, with offices at 2275 Half Day Road, Suite 200, Bannockburn, IL 60015 ("Licensee"). Licensor and Licensee are hereinafter referred to individually as a "Party" and collectively as the "Parties."

Homology Medicines, Inc. – Confidential Treatment Requested by Homology Medicines, Inc. FIRST AMENDMENT TO LICENSE AGREEMENT (March 2nd, 2018)

This amendment to the License Agreement (the First License Amendment), effective on the date last signed below, (Amendment Effective Date) is by and between Homology Medicines, Inc., a Delaware corporation having a place of business at 45 Wiggins Avenue, Bedford, MA 01730 (HMI) and California Institute of Technology, a not-for-profit corporation duly organized and existing under the laws of the State of California with an address at 1200 East California Boulevard, MC 6-32, Pasadena, California 91125 (Caltech; HMI and Caltech together are the Parties).

AveXis, Inc. – First Amendment to License Agreement (February 28th, 2018)

This First Amendment to License Agreement (the "First Amendment") is made as of January 8, 2018 (the "First Amendment Effective Date") by and between REGENXBIO Inc. (formerly known as ReGenX Biosciences, LLC), a corporation organized under the laws of the State of Delaware, with offices at 9600 Blackwell Road, Suite 210, Rockville, MD 20850 ("Licensor"), and AveXis, Inc., a corporation organized under the laws of the State of Delaware, with offices at 2275 Half Day Road, Suite 200, Bannockburn, IL 60015 ("Licensee"). Licensor and Licensee are hereinafter referred to individually as a "Party" and collectively as the "Parties."

Homology Medicines, Inc. – Confidential Treatment Requested by Homology Medicines, Inc. FIRST AMENDMENT TO LICENSE AGREEMENT (January 30th, 2018)

This amendment to the License Agreement (the First License Amendment), effective on the date last signed below, (Amendment Effective Date) is by and between Homology Medicines, Inc., a Delaware corporation having a place of business at 45 Wiggins Avenue, Bedford, MA 01730 (HMI) and California Institute of Technology, a not-for-profit corporation duly organized and existing under the laws of the State of California with an address at 1200 East California Boulevard, MC 6-32, Pasadena, California 91125 (Caltech; HMI and Caltech together are the Parties).

Level Brands, Inc. – First Amendment to License Agreement (January 22nd, 2018)

THIS FIRST AMENDMENT ("First Amendment") is entered into as of January 19, 2018, by and between Isodiol International Inc., a Canadian corporation ("Licensee"), and Level Brands, Inc., a North Carolina corporation ("Licensor"), and amends, modifies, and supplements that certain License Agreement dated as of December 30, 2017 between the parties (the "Agreement").

GraniteShares Platinum Trust – Amendment to License Agreement (January 12th, 2018)

This Amendment (the "Amendment") is made as of November 3, 2017 by and between GRANITESHARES LLC ("Licensee") and THE BANK OF NEW YORK MELLON ("Licensor").

resTORbio, Inc. – [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED First Amendment to License Agreement (December 29th, 2017)

First Amendment to License Agreement (Amendment), made as of October 3, 2017 (Amendment Effective Date), to the License Agreement (Original Agreement), dated March 23, 2017 (the Original Agreement Effective Date), by and between Novartis International Pharmaceutical Ltd., a for-profit corporation with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (Novartis) and resTORbio, Inc., a Delaware corporation located at 501 Boylston Street, Suite 6102, Boston, Massachusetts 02116 (resTORbio). The Original Agreement, as amended by this Amendment, is referred to as the Agreement. Novartis and resTORbio are each referred to individually as a Party and together as the Parties.

resTORbio, Inc. – [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED First Amendment to License Agreement (December 22nd, 2017)

First Amendment to License Agreement (Amendment), made as of October 3, 2017 (Amendment Effective Date), to the License Agreement (Original Agreement), dated March 23, 2017 (the Original Agreement Effective Date), by and between Novartis International Pharmaceutical Ltd., a for-profit corporation with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (Novartis) and resTORbio, Inc., a Delaware corporation located at 501 Boylston Street, Suite 6102, Boston, Massachusetts 02116 (resTORbio). The Original Agreement, as amended by this Amendment, is referred to as the Agreement. Novartis and resTORbio are each referred to individually as a Party and together as the Parties.

Athersys – First Amendment to License Agreement (November 8th, 2017)

This First Amendment to the License Agreement (the First Amendment) is dated July 21, 2017 and amends the License Agreement dated January 8, 2016 (the Agreement) by and between ABT Holding Company (ATHX), a Delaware corporation having its principal place of business at 3201 Carnegie Avenue, Cleveland, OH 44115 and wholly-owned subsidiary of Athersys, Inc. (Athersys), and HEALIOS, K.K. (Healios), a Japanese company having its principal place of business at World Trade Center Bldg. 15F, 2-4-1 Hamamatsucho, Minato-ku, Tokyo 105-6115 Japan. All defined terms used but not defined in this First Amendment shall have the meanings ascribed to them in the Agreement.